Argenx
ARGX
#440
Rank
NZ$101.01 B
Marketcap
NZ$1,616
Share price
0.34%
Change (1 day)
77.84%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$27.78. In 2025 the company made an earnings per share (EPS) of NZ$37.04 an increase over its 2024 EPS that were of NZ$24.46.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-26.49%
2025NZ$37.0451.44%
2024NZ$24.46-369.77%
2023NZ-$9.07-60.46%
2022NZ-$22.9363.33%
2021NZ-$14.04-40.37%
2020NZ-$23.54183.47%
2019NZ-$8.31123.09%
2018NZ-$3.7254.93%
2017NZ-$2.4014.07%
2016NZ-$2.1113.05%
2015NZ-$1.86-36.34%
2014NZ-$2.93209.04%
2013NZ-$0.95-33.99%
2012NZ-$1.43185.59%
2011NZ-$0.50